This site is intended only for healthcare professionals resident in the United Kingdom
Prescribing information can be found at the bottom of the page
ZYVOX is indicated for NP and CAP when known or suspected to be caused by susceptible Gram positive bacteria and in cSSTI only when microbiological testing has established that the infection is known to be caused by susceptible Gram positive bacteria. ZYVOX should only be initiated in a hospital environment and after consultation with a relevant specialist such as a microbiologist or infectious disease specialist1.
ZYVOX (linezolid) offers effective intervention for nosocomial pneumonia (NP), community acquired pneumonia (CAP) and complicated skin and soft tissue infections (cSSTI) caused by susceptible Gram positive pathogens1
NP & CAP
ZYVOX is not active against infections caused by Gram negative pathogens. Specific therapy against Gram negative organisms must be initiated concomitantly if a Gram negative pathogen is documented or suspected1.
ZYVOX is not active against infections caused by Gram negative pathogens. Linezolid should only be used in patients with complicated skin and soft tissue infections with known or possible co-infection with Gram negative organisms if there are no alternative treatment options available. In these circumstances treatment against Gram negative organisms must be initiated concomitantly1.
ZYVOX is a synthetic, antibacterial agent that belongs to the oxazolidinones class of antibiotics. It has in vitro activity against aerobic Gram positive bacteria and anaerobic micro-organisms. ZYVOX selectively inhibits bacterial protein synthesis by binding to a site on the bacterial ribosome (23S of the 50S subunit) and prevents the formation of a functional 70S initiation complex which is an essential component of the translation process1.
CAP, community acquired pneumonia; cSSTI, complicated skin and soft tissue infections; NP, nosocomial pneumonia.
- ZYVOX® Summary of Product Characteristics